- Home
- TCRT vs XAIR Comparison
TCRT vs XAIR Comparison
Compare TCRT & XAIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TCRT | XAIR |
|---|---|---|
| Founded | 1998 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.9M | 4.3M |
| IPO Year | 2025 | 2015 |
Fundamental Metrics
Financial Performance| Metric | TCRT | XAIR |
|---|---|---|
| Price | $1.76 | $5.29 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $10.00 |
| AVG Volume (30 Days) | 8.9K | ★ 43.2K |
| Earning Date | 05-14-2026 | 06-16-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 24.66 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $15,900,000.00 | $7,679,000.00 |
| Revenue This Year | N/A | $122.00 |
| Revenue Next Year | N/A | $58.15 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 107.26 |
| 52 Week Low | $1.75 | $0.33 |
| 52 Week High | $4.57 | $8.19 |
Technical Indicators
Market Signals| Indicator | TCRT | XAIR |
|---|---|---|
| Relative Strength Index (RSI) | 29.15 | 49.68 |
| Support Level | N/A | $5.06 |
| Resistance Level | $2.02 | $7.72 |
| Average True Range (ATR) | 0.09 | 0.71 |
| MACD | -0.01 | -0.25 |
| Stochastic Oscillator | 9.37 | 8.06 |
Price Performance
Historical ComparisonAbout TCRT Alaunos Therapeutics Inc.
Alaunos Therapeutics Inc is a preclinical-stage biopharmaceutical company focused on the development of novel, orally administered small-molecule therapeutics for obesity and related metabolic disorders, such as metabolic dysfunction-associated steatotic liver disease (MASLD, a type of fatty liver disease). The program aims to develop a differentiated, non-hormonal, non-incretin approach, unlike hormone-based treatments like GLP-1 drugs. It has a single reportable and operating segment related to biopharmaceutical research and development.
About XAIR Beyond Air Inc.
Beyond Air Inc a commercial-stage medical device and biopharmaceutical company developing a platform of nitric oxide (NO) generators and delivery systems (the LungFit platform) capable of generating NO from ambient air. Its segments are Beyond Air, Beyond Cancer, and NeuroNos. The company generates majority of revenue from Beyond Air. It has developed the Beyond Air NO generator and delivery system which it call LungFit, a novel and precise delivery system that uses NO generated from ambient air with a novel NO generator, the ionizer. Its product and technology includes LungFitPH.